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Summary
Background Worry might be a contributory causal factor in the occurrence of persecutory delusions in patients with 
psychotic disorders. Therefore we postulated that reducing worry with cognitive behaviour therapy (CBT) would 
reduce persecutory delusions.
Methods For our two-arm, assessor-blinded, randomised controlled trial (Worry Intervention Trial [WIT]), we recruited 
patients aged 18–65 years with persistent persecutory delusions but non-aﬀ ective psychosis from two centres: the Oxford 
Health National Health Service (NHS) Foundation Trust (Oxford, UK) and the Southern Health NHS Foundation Trust 
(Southampton, UK). The key inclusion criteria for participants were a score of at least 3 on the Psychotic Symptoms 
Rating Scale (PSYRATS) denoting a current persecutory delusion; that the delusion had persisted for at least 3 months; a 
clinical diagnosis of schizophrenia, schizoaﬀ ective disorder, or delusional disorder; and a clinically signiﬁ cant level of 
worry. We randomly assigned (1:1) eligible patients, using a randomly permuted block procedure with variable block sizes 
and division by four strata, to either six sessions of worry-reduction CBT intervention done over 8 weeks added to standard 
care (the CBT-intervention group), or to standard care alone (the control group). The assessors were masked to patient 
allocations and did their assessments at week 0 (baseline), 8 weeks (end of treatment), and 24 weeks, follow-up. The 
primary outcomes were worry measured by the Penn State Worry Questionnaire (PSWQ) and delusions measured by the 
PSYRATS-delusion scale; we did the analyses in the intention-to-treat population, and also did a planned mediation 
analysis. This trial is registered with the ISRCTN Registry (number ISRCTN23197625) and is closed to new participants.
Findings From Nov 1, 2011, to Sept 9, 2013, we recruited 150 eligible participants and randomly assigned 73 to the CBT 
intervention group, and 77 to the control group. 143 patients (95%) provided primary outcome follow-up data. 
Compared with standard care alone, at 8 weeks the CBT intervention signiﬁ cantly reduced worry (mean diﬀ erence 
6·35 [SE 1·56] PSWQ units, 95% CI 3·30–9·40; p<0·001) and persecutory delusions (2·08 [SE 0·73] PSYRATS units, 
95% CI 0·64–3·51; p=0·005). The reductions were maintained to 24 weeks follow-up. The mediation analysis 
suggested that the change in worry accounted for 66% of the change in delusion. No patients died or were admitted 
to secure units during our study. Six suicide attempts (two in the CBT intervention group, and four in the control 
group) and two serious violent incidents (one in each group) were noted, but no adverse events were deemed related 
to the treatments or the assessments.
Interpretation To our knowledge, this is the ﬁ rst large trial focused on persecutory delusions. We have shown that 
long-standing delusions were signiﬁ cantly reduced by a brief intervention targeted on worry, although the limitations 
for our study include no determination of the key elements within the intervention. Our results suggest that worry 
might cause paranoia, and that worry intervention techniques might be a beneﬁ cial addition to the standard treatment 
of psychosis.
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Introduction
Treatments for psychotic disorders such as schizophrenia 
need substantial improvement. Our approach is to study 
single psychotic experiences such as persecutory 
delusions, establish a theoretical model, and translate 
the knowledge gained into treatment. To build the 
treatment, one putative causal factor is taken at a time, 
changed, and the eﬀ ect on the psychotic occurrence 
examined.1 This approach is called an interventionist-
causal model approach.2 In this Article, we report the 
eﬀ ects of targeting one causal factor—worry—in 
patients with persecutory delusions.
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Worry is an expectation of the worst happening. It 
consists of repeated negative thoughts about potential 
adverse outcomes, and is a psychological component of 
anxiety. Worry brings implausible ideas to mind, keeps 
them there, and increases the level of distress. Therefore 
we have postulated that worry is a causal factor in the 
development and maintenance of persecutory delusions, 
and have tested this theory in several studies.3–9 We 
showed that levels of worry in patients with persecutory 
delusions are similar to those noted in generalised 
anxiety disorder;3 a dose-response association exists 
between levels of worry and paranoia;4 worry is a 
predictor of the occurrence and persistence of non-
clinical paranoia in the general population5,6 and in 
experimental settings;7 and levels of worry predict the 
persistence of persecutory delusions.8,9 Other study 
groups are also replicating and extending these 
ﬁ ndings.10,11 We have translated this knowledge into 
treatment and shown in a pilot trial12 that a brief 
intervention of worry-reduction added to standard care 
might lead to reductions in both worry and persecutory 
delusions. In the terminology of the scientiﬁ c literature, 
worry in delusions is a so-called inus condition—“an 
insuﬃ  cient but non-redundant part of an unnecessary 
but suﬃ  cient disorder.”13 Persecutory delusions arise 
from a combination of causes, with each causal factor 
increasing the probability of such fears occurring.
We planned our trial as a rigorous test of these 
mechanistic links to inform both theory and treatment. 
A key mechanism (worry) was targeted. The appropriate 
control condition was a standard care group to establish 
that the mechanism had been successfully targeted, 
which would then allow examination of the eﬀ ects of the 
mechanism change on the central clinical occurrence 
(persecutory delusions). We planned an elaborate 
mediation analysis to substantiate the postulated 
mechanism of delusion change. The aim of our study 
was to investigate whether the intervention with 
cognitive behaviour therapy (CBT) would reduce levels 
of worry in patients with persecutory delusions and 
reduce the delusions themselves; the improvements 
would be maintained at follow-up; and the reduction in 
worry would mediate changes in persecutory delusions.
Methods
Study design and participants
We did a randomised, controlled, single-blind trial in two 
UK centres: the Oxford Health National Health Service 
(NHS) Foundation Trust, Oxford, and the Southern 
Health NHS Foundation Trust, Southampton. These 
large mental health services cover populations of about 
1·2 million people each. The trial received a favourable 
opinion from an NHS Research Ethics Service Committee, 
and the trial protocol has been published.14 We sought 
referrals of patients aged 18–65 years with persecutory 
delusions from both centres. The inclusion criteria were: 
a current persecutory delusion as deﬁ ned by Freeman and 
Garety,15 scoring at least 3 on the conviction scale of the 
Psychotic Symptoms Rating Scale (PSYRATS);16 that the 
delusion had persisted for at least 3 months; a clinical 
diagnosis of schizophrenia, schizoaﬀ ective disorder, or 
delusional disorder (ie, a diagnosis of non-aﬀ ective 
psychosis); and a clinically signiﬁ cant level of worry, as 
shown by a score of more than 44 on the Penn State Worry 
Questionnaire (PSWQ).17 Where major changes in drugs 
were going to be made, entry to the investigation would 
not occur until at least 1 month after stabilisation of 
dosage. Criteria for exclusion were: a primary diagnosis of 
alcohol or substance dependency or personality disorder; 
an organic syndrome or learning disability; a command of 
spoken English that was inadequate for engaging in 
therapy; and currently having individual CBT. All patients 
provided written informed consent.
Randomisation and masking
We randomly assigned (1:1) eligible patients, after a 
baseline assessment, to either six sessions of CBT 
worry-reduction intervention done over 8 weeks added 
to standard care (the CBT intervention group), or to 
standard care alone (the control group). We used a web-
based randomisation system, written by the Oxford 
Clinical Trials Unit for Mental Illness with a stratiﬁ ed 
randomisation procedure including four strata and a 
randomly permuted block procedure with variable 
block sizes. We did the stratiﬁ cation on the basis of 
centre and level of worry (deﬁ ned as moderate when 
the PSWQ worry score was 44–62, and high when the 
score was ≥63).
The assessors were masked to patients’ treatment 
allocations, but all patients were informed of their 
allocation by a trial therapist. Precautionary strategies 
included thinking about the best room to use and diary 
arrangements; patients being reminded by the assessors 
not to talk about allocation; and, after the initial 
assessment, the assessors did not look at clinical notes. If 
an allocation was revealed to the assessor, then remasking 
occurred, by use of another rater, which happened 
11 times. However, if an allocation was revealed during 
an assessment session then these ratings were used: two 
8-week assessments (both with the intervention) and 
four 24-week assessments (three with the intervention) 
were done unmasked.
Procedures
We aimed to provide the CBT worry-reduction inter-
vention in six sessions over 8 weeks. Each session lasted 
roughly an hour and took place in NHS clinics or at 
patients’ homes. Therapy was delivered individually. 
Before therapy began the clinician met the patient for an 
initial introduction and assessment. The assessments of 
outcome measures were completed at 0 weeks (baseline), 
8 weeks (end of therapy), and at 24 weeks (follow-up). 
Three graduate psychologists (EČ, GW, and KS) did the 
enrolment and assessments.
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The highly detailed intervention is designed to provide 
clear and simple messages for patients to take into their 
day-to-day lives. We wrote a set of six session booklets, 
shared by the patient and therapist. The worry reduction 
strategies included have been shown to be eﬀ ective at 
reducing worry and do not challenge the delusion itself. 
The main techniques were psychoeducation about 
worry, identiﬁ cation and reviewing of positive and 
negative beliefs about worry, increasing awareness of 
the initiation of worry and individual triggers, use of 
worry periods, planning activity at times of worry (which 
could include relaxation), and learning to let go of worry. 
We formulated a so-called worry cycle early in the 
intervention: feeling under threat leads to activation of 
positive beliefs about worry and hence engagement in 
this thinking style, resulting in dwelling on the worst 
outcomes and an increase in the initial feelings of 
threat. The worry cycle was discussed in relation to a 
recent bout of worry by the patient. Tasks were set 
between sessions—eg, imple mentation of worry 
periods. Whenever patients agreed, the trial therapists 
telephoned or texted them between sessions, to 
encourage them to try the new strategies. We helped 
patients to learn that they had understandable positive 
beliefs about worry (eg, that worry kept them safe) that 
meant that they engaged with this thinking style. They 
were helped to see the skewed view that worry provides 
and how it exacerbates fears. The two main practical 
techniques to reduce worry were then introduced: the 
use of worry periods (conﬁ ning worry to about a 20 min 
set period each day) and planning of activities at peak 
worry times. Worry periods were implemented ﬂ exibly. 
For example, most patients set up one worry period a 
day, but they could choose to have two worry periods a 
day or, in severe instances, patients instead aimed for a 
worry-free period. Ideally, the worry period was then 
substituted with a problem-solving period. Our general 
approach and techniques are also described in a 
treatment book.18
Three clinical psychologists provided therapy (KP, JC, 
and HM), and were supervised each week by DF and HS. 
One of the therapists provided the intervention for all 
participants in Oxford (KP). The trial began with another 
therapist (JC) providing all therapy in Southampton, 
although in the latter part of the trial a third therapist 
took over (HM). We recorded therapy sessions when 
patients gave permission. To assess treatment ﬁ delity, 
12 recordings, chosen randomly, were rated on the 
Cognitive Therapy Scale—Revised (CTSR)19 by an 
independent clinical psychologist who was skilled in 
CBT for psychosis. All chosen recordings were rated as 
providing at least satisfactory cognitive therapy (ie, a 
mean score of at least 3).
Standard care was delivered according to national and 
local service protocols and guidelines. This usually 
consists of prescription antipsychotic drugs, visits from a 
community mental health worker, and regular outpatient 
appointments with a psychiatrist. It was recorded with 
the Client Service Receipt Inventory.20
Outcomes
The pre-speciﬁ ed primary outcome measures were levels 
of worry assessed by the PSWQ21 and levels of persecutory 
delusions assessed by the PSYRATS-delusions scale.16 
High scores on these scales indicate high levels of worry 
and delusions, respectively. Secondary outcome measures 
were delusion distress measured by the PSYRATS-distress 
scale; total psychiatric symptoms measured by the Positive 
and Negative Syndromes Scale (PANSS);22 paranoia 
Figure 1: Trial proﬁ le
PSWQ=Penn State Worry Questionnaire. CBT=cognitive behavioural therapy.
73 allocated to worry-reduction 
CBT intervention plus
standard care
64 received allocated 
intervention
9 did not receive allocated 
intervention (deﬁned as 
three or fewer sessions) 
3 lost to 
follow-up 
4 lost to 
follow-up 
77 allocated to control 
(standard care alone) 
70 attended 8 week follow-up 73 attended 8 week follow-up 
68 attended 24 week follow-up 73 attended 24 week follow-up 
73 analysed (intention-to-treat
population) 
77 analysed (intention-to-treat
population) 
5 lost to 
follow-up 
4 lost to 
follow-up 
150 randomised 
276 assessed for eligibility 
441 participants referred 
113 were excluded
8 had insuﬃcient score on PSWQ
102 had no current persecutory delusion
2 had insuﬃcient capacity to consent
1 was too acutely unwell to engage
13 were suitable but declined to participate
163 declined to be screened
2 excluded because of high forensic risk
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measured by the Green et al Paranoid Thoughts Scale 
(GPTS);23 rumination measured by the Perseverative 
Thinking Questionnaire (PTQ);24 an adapted service user-
led measure of patient outcomes (CHOICE)25 assessing—
eg, self-conﬁ dence, having coping strategies, and a sense 
of being in control; and wellbeing measured by the 
Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS).26 
High scores on these scales indicate delusion distress, 
higher overall levels of psychiatric symptoms, paranoia, 
rumination, patient satisfaction, and psychological 
wellbeing. We tested interrater reliability for the two 
interviewer-rated assessments, with two-way mixed, one-
measure intraclass correlations (ICC).
At baseline, to examine additional moderators of out-
come, participants completed assessments of intel lectual 
functioning (the Wechsler Adult Intelligence Scale 
[WAIS]),27 illicit drug use (the Maudsley Addiction Proﬁ le),28 
illness and treatment representations,29 probabilistic 
reasoning,30 and working memory (appendix).31,32
During the trial, we recorded any adverse event that 
came to our attention. We also checked medical notes at 
the end of the trial for the following events prespeciﬁ ed 
as adverse: all deaths, suicide attempts, serious violent 
incidents, admissions to secure units, and formal 
complaints about therapy.
Statistical analysis
Our target sample size was 150 patients, split equally 
between the two centres. We wanted to detect moderate 
or large eﬀ ects. A simple two-tailed t-test with 60 people 
per group would provide 90% power to detect an eﬀ ect 
size of 0·60 at a signiﬁ cance level of 0·05, and would 
have 80% power to detect an eﬀ ect size of 0·52. In 
practice, further power would be gained by use of 
multiple regression. Therefore, conservatively allowing 
for a 20% dropout, 150 people would need to be recruited 
to enable full data to be obtained from 120 participants.
We did all main analyses at the end of the last follow-up 
assessments at week 24 (ie, we did not do any interim 
analyses) with Stata version 13,33 in the intention-to-treat 
population, with due consideration being given to potential 
biases arising from loss to follow-up. Random or mixed 
eﬀ ects models (with Stata’s xtreg command) were ﬁ tted to 
the repeated measures to estimate treatment eﬀ ects for 
outcomes, controlling for stratum (treatment centre 
crossed by the initial level of worry; ie, moderate or high), 
and the corresponding baseline assessment for the 
outcome being investigated. To ﬁ nd out whether the 
intervention eﬀ ects diﬀ ered at 8 weeks compared with 
24 weeks (ie, whether eﬀ ects were maintained), we also 
tested treatment by follow-up time interactions; this 
analysis tested whether diﬀ erences in the intention-to-treat 
eﬀ ects at the two follow-up times were signiﬁ cant. We 
allowed for the presence of missing outcome data under 
the assumption that the data were missing at random.34 We 
calculated standard eﬀ ect sizes (Cohen’s d) by dividing the 
estimated treatment eﬀ ects by the pooled SD at follow-up.
We did all mediation analyses using the structural 
equation modelling package Mplus Version 7 (appendix).35 
Our mediation analysis strategy was similar to that 
advocated by Baron and Kenny36—ie, we tested for 
intervention eﬀ ects on the outcome (delusions) and on 
the proposed mediator, then ﬁ tted a full model to estimate 
the direct and indirect eﬀ ects of the intervention on 
outcome—but with statistical models that account for the 
repeated measures of both mediator and outcome (ie, a 
parallel process model),37 acknowledge that confounding 
of the eﬀ ect of mediator on outcome is probable,38 and 
allow for the fact that the mediator and outcome are 
subject to substantial measurement error.39
CBT intervention 
group (n=73)
Control group 
(n=77)
Age (years) 40·9 (10·5) 42·1 (12·2)
Sex
Male 42 (58%) 44 (57%)
Female 31 (42%) 33 (43%)
Ethnic origin
White 68 (93%) 69 (89%)
Black 1 (1%) 0 (0%)
Chinese 0 (0%) 2 (3%)
Indian 0 (0%) 3 (4%)
Other 4 (6%) 3 (4%)
Employment status
Unemployed 55 (75%) 51 (66%)
Part-time employed 8 (12%) 6 (7%)
Full-time employed 3 (4%) 10 (13%)
Self employed 1 (1%) 2 (3%)
Retired 2 (3%) 6 (8%)
Student 1 (1%) 2 (3%)
Housewife or husband 3 (4%) 0 (0%)
Intelligence quotient 100·3 (19·0) 101·8 (18·2)
Diagnosis
Schizophrenia 58 (79%) 53 (69%)
Schizoaﬀ ective disorder 5 (7%) 6 (7%)
Delusional disorder 4 (5%) 6 (7%)
Psychosis NOS 6 (8%) 12 (16%)
Outpatient 71 (97%) 76 (99%)
Inpatient 2 (3%) 1 (1%)
Inpatient admission in 
previous 6 months
10 (14%) 8 (10%)
Chlorpromazine-equivalent 
dose of antipsychotic drug 
(mg/day)
523·2 (394·3) 475·5 (420·6)
Time in contact with services
<1 year 5 (8%) 7 (9%)
1–5 years 12 (16%) 17 (22%)
6–10 years 16 (22%) 12 (16%)
11–20 years 18 (25%) 26 (34%)
>20 years 21 (29%) 15 (19%)
Data are n (%) or mean (SD). NOS=not otherwise speciﬁ ed.
 Table 1: Baseline characteristics of the intention-to-treat population
See Online for appendix
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We used data from both treatment groups in these 
analyses—essentially assessing what proportion of the 
intention-to-treat eﬀ ect of the worry intervention on 
delusions is attributed to its eﬀ ect on worry. All statistical 
testing was two-tailed.
Level of worry was assumed to be the mediator and 
severity of paranoia the ﬁ nal outcome (rather than vice 
versa)—primarily motivated by the fact that the 
intervention was speciﬁ cally targeted on worry as the 
mechanism of change. The parameters of the chosen 
model were then estimated assuming the underlying 
validity of the model.
We started with two simple measurement or factor 
analysis models—the ﬁ rst for worry and the second for 
delusions. In each case, the loadings for 8 and 24 weeks 
were constrained to be 1, the intercept term for each 
timepoint was constrained to be 0, and the variances of the 
measurement errors were equal for the two timepoints. 
We assumed that measurements at the follow-up times 
were parallel measures of a stable underlying latent 
variable.35 The measurement errors for worry and 
delusions were correlated at 8 weeks and 24 weeks.
We estimated the eﬀ ects of the intervention on the worry 
outcome factor, the delusions outcome factor, and the 
eﬀ ect of the worry factor on the outcome factor, allowing 
for a direct eﬀ ect of the intervention on the outcome. In 
practice, the worry and delusions outcome factors were 
assessed in a joint structural equation model, allowing for 
the residual (ie, not accounted for by the intervention and 
baseline covariates) variation in worry and delusion to be 
correlated (as would be expected if mediation were 
present). For the eﬀ ect of worry on the outcome, we jointly 
modelled the eﬀ ect of the intervention on worry and the 
eﬀ ect of worry and the intervention on outcome (this time 
not allowing the residuals to be correlated).
We allowed for confounding mainly by inclusion of the 
baseline values of both worry and delusions (in addition 
to the stratifying factors) in all the structural equation 
model analyses. In the intention-to-treat analyses there 
was no diﬃ  culty of confounding and the covariates were 
included to strengthen precision. In the mediation 
analysis we looked at a non-randomised comparison 
(neither mediator or outcome are under the direct control 
of the investigator), and confounding might therefore be 
present. A major source of such confounding is likely to 
be the correlation between the baseline values of worry 
and delusions (estimated here to be 0·51).
The main mediation analysis model was essentially 
equivalent to an analysis of covariance model for the 
eﬀ ects on the intervention on the latent outcome common 
to 8 weeks and 24 weeks outcome, conditioning on the 
corresponding latent mediator and baseline covariates. 
An alternative approach to the analysis might have been 
through the use of latent change score models37—but, if 
no changes were shown in either mediator or outcomes 
between 8–24 weeks follow-up, the results of ﬁ tting an 
appropriately parameterised and constrained latent 
change model would yield identical results (ie, identical 
goodness-of-ﬁ t indices and identical parameter estimates 
for the direct and indirect eﬀ ects of the intervention; 
appendix). A data monitoring and ethics committee 
oversaw our study. This trial is registered with the 
ISRCTN Registry, number ISRCTN23197625.
Role of the funding source
The funder of the study reviewed the application for the 
trial and monitored the progress of trial milestones (eg, 
recruitment). The funder had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between Nov 1, 2011, to Sept 9, 2013, with the last 
assessments completed on March 10, 2014, we assessed 
276 participants, of whom 150 were eligible, gave 
imformed consent, and were randomly assigned to 
either the CBT intervention group (n=73) or to the 
control group (n=77; ﬁ gure 1). As with other studies of 
persistent psychotic occurrences, both groups had a 
Panel 1: Patient comments on the intervention
Patient 1
“The discussions about preventing worry and reducing worry were extremely helpful to 
me. It made me see my worry as something real. The breakthrough was that I was able to, 
with the help of my psychologist, come up with a strategy—that is, when worry [was] 
gripping me I would say “’excuse me worry, while I do…’” or “’excuse me worry, I need  to 
interrupt you because….’” I sometimes worry about people trying to harm me but now 
I can interrupt my worry and do something else. I challenge myself to do this because 
I know it works for me.”
Patient 2
“I had no conﬁ dence in who I was and felt I avoided everyone because of my thoughts and 
being in company was really frightening. I found the therapy challenging and sometimes 
very diﬃ  cult. But it was eye-opening as I didn’t realise how much I worried and where the 
worry was coming from. To see it on paper made it more straightforward and made my 
life more clear. I do feel that I now try to take time out, whether that’s a cup of tea or 
going to the shops. Just doing things that I actually enjoy doing and building on them as 
I was so wrapped up in anxiety I was lost. I am more relaxed at certain times of the day 
where I was once completely stressed. I still ﬁ nd it hard around people but I feel I can still 
build on the skills you gave me and if it’s slightly better, that’s good.”
Patient 3
“The therapy was very rewarding. There wasn’t anything I didn’t like. I needed that kind of 
therapy at the time because if I didn’t have that therapy at that time, I wouldn’t be here. It 
was therapeutic talking about things. I listened to what you had to say and wrote down 
how I felt. I also tried relaxing to the tape and I ignored people when they were horrible to 
me. It was hard becoming disciplined but we worked as a team, that’s what I liked about it. 
You don’t get nowhere in this world if you don’t work as a team. I was having a hard time 
and you was doing your best to stop me having a hard time. That’s what I call team work; 
I couldn’t have been able to do it by myself, no way. I thought a lot about what I thought 
the therapy did—it decreased my worrying but in other ways it built my conﬁ dence.”
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slightly higher preponderance of men than women, the 
mean age was around 40 years, most were unemployed, 
and the main psychiatric diagnosis was schizophrenia. 
All but nine patients were taking antipsychotic drugs 
(one in the CBT group, eight in the control group). Most 
patients had been in contact with mental health services 
for many years (table 1).
The mean number of sessions received was 5·5 (SD 1·8); 
51 patients attended six sessions. In the interest of 
ﬂ exibility, for a few patients the intervention was provided 
in seven (n=7) or eight sessions (n=2) during the 8 week 
period. Two patients attended no therapy sessions. The 
remainder of the patients attended one (n=5), two (n=1), 
three (n=1), four (n=3), or ﬁ ve (n=1) sessions. Panel 1 
shows patient comments about the intervention. An 
analysis of the eﬀ ects of increasing compliance with 
therapy had been proposed in the published trial protocol14 
but, in the event, compliance with the allocated intervention 
was so high that such an analysis was deemed unnecessary.
The therapist in Oxford provided the intervention to 
37 participants. The two therapists in Southampton 
provided the intervention to 22 and 14 participants, 
respectively. The number of trial participants that can be 
used as controls for each of these three therapists was 
37 for Oxford, and 23 and 13 for Southampton. In the 
sensitivity analyses allowing for therapist eﬀ ects described 
in the section on mediation, trial participants were, in 
eﬀ ect, stratiﬁ ed by therapist instead of centre. For inter-
rater reliability tests, when rater 1 attended 23 assessments 
with rater 2, their reliability ratings were PSYRATS total 
ICC=0·99, PANSS total ICC=0·83. Rater 1 attended 
18 assessments with rater 3 and their reliability ratings 
were PSYRATS total ICC=0·98, PANSS total ICC=0·75.
When compared with standard care alone, the CBT 
intervention led to a signiﬁ cant reduction in levels of 
worry (table 2). The estimated mean diﬀ erence in PSWQ 
scores at 8 weeks between the CBT-intervention group 
and the control group was 6·35 (SE 1·56; 95% CI 
3·30–9·40; p<0·001). Persecutory delusions were also 
reduced in the CBT-intervention group compared with 
the control group; the estimated mean diﬀ erence in 
PSYRATS scores at 8 weeks in the intervention group 
compared with the standard care group was 2·08 (SE 0·73; 
95% CI 0·64–3·51; p=0·005). The mean treatment by 
follow-up time (8 and 24 weeks) interactions were 
estimated to be –2·43 PSWQ (SE 1·57; p=0·121) and 
0·86 PSYRATS (SE 0·68; p=0·205), suggesting that at 
24 weeks, the treatment eﬀ ects were smaller for PSWQ, 
but larger for PSYRATS. However, neither of these 
interactions were signiﬁ cant and the statistical models 
were reﬁ ned to estimate treatment eﬀ ects (ie, diﬀ erences 
in average outcome between the two randomised groups) 
that were assumed to be common to both follow-up 
times. The resulting treatment-eﬀ ect estimates were 
5·15 (SE 1·35; 95% CI 2·50–7·79; p<0·001; Cohen’s 
d=0·47) and 2·50 (SE 0·65; 95% CI 1·22–3·78; p<0·001; 
Cohen’s d=0·49). No substantial temporal trends in the 
mediator or the outcome between 8 and 24 weeks were 
noted, substantially simplifying the statistical models 
needed for the analysis of the associations between 
changes in the mediator and the corresponding changes 
in clinical outcome.
Signiﬁ cant improvements were noted with the CBT 
treatment for all the secondary outcome measures. There 
were no signiﬁ cant treatment by follow-up time inter-
actions (ie, intention-to-treat eﬀ ects did not signiﬁ cantly 
diﬀ er between 8 weeks and 24 weeks), and therefore 
treatment estimates common to both follow-ups were 
made. Compared with standard care alone, CBT inter-
vention reduced mean PSYRATS distress scores (0·85, 
CBT intervention group Control group
n Mean (SD) n Mean (SD)
Primary measures
Worry (PSWQ)
0 weeks 73 64·8 (8·6) 77 64·5 (9·5)
8 weeks 70 54·8 (10·5) 73 61·0 (12·2)
24 weeks 68 56·1 (9·7) 73 59·8 (11·0)
Delusion (PSYRATS-delusion)
0 weeks 73 18·7 (3·0) 77 18·0 (3·0)
8 weeks 70 14·3 (4·8) 73 15·9 (5·1)
24 weeks 68 13·6 (5·6) 72 16·4 (4·8)
Secondary measures
Delusion distress (PSYRATS-distress)
0 weeks 73 6·4 (1·4) 77 6·5 (1·3)
8 weeks 70 5·1 (1·9) 73 5·8 (2·1)
24 weeks 68 5·0 (2·2) 72 6·1 (1·8)
Total symptoms (PANSS)
0 weeks 73 82·0 (13·6) 76 79·0 (13·5)
8 weeks 69 70·7 (12·4) 73 75·3 (16·0)
24 weeks 68 71·5 (15·4) 71 76·3 (16·7)
Paranoia (GPTS)
0 weeks 73 115·9 (27·3) 77 110·8 (27·8)
8 weeks 70 90·0 (32·2) 73 102·3 (31·7)
24 weeks 67 92·5 (32·7) 73 105·6 (32·4)
Rumination (PTQ)
0 weeks 70 44·3 (9·7) 72 44·9 (9·8)
8 weeks 68 37·7 (9·7) 70 41·0 (11·7)
24 weeks 64 37·3 (10·5) 71 42·7 (10·6)
Patient outcomes (CHOICE)
0 weeks 71 49·4 (17·3) 75 49·5 (18·5)
8 weeks 67 64·4 (17·1) 69 51·7 (21·1)
24 weeks 66 61·6 (21·4) 70 52·5 (22·4)
Wellbeing (WEMWBS)
0 weeks 73 36·4 (9·6) 77 34·5 (9·2)
8 weeks 68 41·5 (9·1) 73 36·5 (11·3)
24 weeks 67 40·2 (10·8) 73 36·6 (10·5)
CBT=cognitive behavioural therapy. PSWQ=Penn State Worry Questionnaire. PSYRATS=Psychotic Symptoms Rating Scale. 
PANSS=Positive and Negative Syndromes Scale. GPTS=Green et al Paranoid Thoughts Scale. PTQ=Perseverative Thinking 
Questionnaire. CHOICE=CHoice of Outcome In Cbt for psychosEs. WEMWBS=Warwick-Edinburgh Mental Wellbeing Scale.
 Table 2: Primary and secondary outcome measures
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SE 0·25, p=0·001, Cohen’s d=0·41), PANSS psychiatric 
symptom scores (6·16, SE 1·69, p<0·001, Cohen’s 
d=0·42), paranoia GPTS scores (14·68, SE 4·18, p<0·001, 
Cohen’s d=0·45), and rumination PTQ scores 
(3·51, SE 1·43, p=0·014, Cohen’s d=0·32). We noted 
improvements in the intervention group versus standard 
care group in psychological wellbeing WEMWBS scores 
(2·40, SE 1·11, p=0·03, Cohen’s d=0·23) and patient 
chosen outcomes CHOICE scores (10·45, SE 2·42, 
p<0·001, Cohen’s d=0·52).
Treatment eﬀ ects were not moderated by centre, 
therapist, level of worry or delusions, intellectual func-
tioning, illicit drug use, illness perceptions, reasoning, or 
working memory (p>0·05).
Figure 2 provides an overview of the mediation analysis. 
The CBT intervention reduced the worry factor by a mean 
of 5·66 (SE 1·32, 95% CI 3·08–8·24; p<0·001) and the 
delusions factor by a mean of 2·33 units (SE 0·64, 95% CI 
1·08–3·58; p<0·001). The intervention directly reduced 
the delusion factor by a mean of 0·80 (SE 0·65, 95% CI 
–0·70 to 2·07; p=0·214). Each unit reduction in the worry 
factor produced a 0·27 change in the delusions factor 
(SE 0·06, 95% CI 0·15–0·39; p<0·001). The estimated 
indirect (mediated) eﬀ ect of the intervention on the 
delusions factor was a reduction of 1·53 (SE 0·49, 95% CI 
0·57–2·48; p=0·002). The proportion of the eﬀ ect of the 
intervention on outcome (delusions) that is mediated by 
changes in worry is therefore 1·53/2·33=66%. The 
structural equation model ﬁ tted the data as shown by a 
χ² score of 20·03 with 17 degrees of freedom (p=0·273), a 
root mean square error of approximation of 0·035, and 
comparative ﬁ t index of 0·992.
One concern about the validity of the estimate of eﬀ ect 
of change in worry on change in delusions came from 
the possibility of confounding arising from diﬀ erential 
therapist eﬀ ects. However, when we used therapist 
identity as a covariate in the models instead of treatment 
centre (but not including a worry stratum by therapist 
interaction), the estimated eﬀ ect of worry on delusions 
was unchanged: 0·27 (SE 0·06). The further addition of 
the therapists by treatment interactions (acknowledging 
that diﬀ erences might occur in the eﬀ ectiveness of the 
therapists) as covariates produced identical results.
The standard care provided for each group was similar 
between groups (table 3). Data for the number of days in 
hospital is skewed for the CBT treatment group, because 
one patient was in hospital for 2 years before entering 
the trial, although they were discharged 3 months into 
the trial.
Two patients did not give us permission to check 
medical notes at the end of the trial. No deaths, 
admissions to secure units, or formal complaints about 
therapy occurred during the trial. There were six suicide 
attempts (two in the treatment group, four in the control 
group) and two serious violent incidents (one in each 
allocation group). None of the adverse events were 
related to therapy or the assessments.
Discussion
The results of the planned analysis were entirely 
consistent with the inference that treating worry in 
patients with persecutory delusions leads to reductions 
in delusions. With the psychological treatment, patients 
also had several other important outcomes, such as a 
reduction in overall levels of psychiatric symptoms and 
general levels of paranoid thinking, and an improvement 
in psychological wellbeing (panel 1, 2).
Traditionally, a fundamental divide has been made 
between neurosis and psychosis. Worry was studied and 
treated in emotional disorders, but not in psychosis. 
Ironically, our WIT study, to our knowledge,40 is the 
largest trial so far of a psychological treatment for 
patients with clinical worry, but it was undertaken in 
patients with diagnoses of psychosis. Our study was 
based on a theoretical understanding of the role of worry 
in delusions, empirical studies that suggested an 
important link, and the results of a promising pilot 
study.12 The group given treatment had severe persecutory 
delusions that had not responded suﬃ  ciently to other 
treatments. The main outcomes were very clear. A brief 
cognitive behavioural intervention for worry, compared 
with treatment as usual, led to signiﬁ cant reductions in 
both worry and the persecutory delusions.
Patients liked the focus on worry, seen in the high 
uptake of the therapy sessions. They agreed that they had 
this problem; nonetheless, by reducing their preoccupation 
with threat and increasing activity levels, the persecutory 
delusions were implicitly challenged. Some patients, by 
being more active with the goal of dealing with worry, 
learned that they were safer outside than they had feared. 
Only eight patients with persecutory delusions were 
excluded from entering the trial on the basis of reporting 
insuﬃ  cient worry. The intervention was deliberately 
highly detailed to help with later dissemination. The 
length of therapy was remarkably short to achieve such 
change in long-standing delusional beliefs. Agreeing to 
six sessions help both the patient and therapist to initiate 
Figure 2: Mediation analysis
Rectangles or squares represent measured variables. Ellipses or circles represent 
latent variables (including random errors or residuals). Single headed arrows 
represent predisposing eﬀ ects; bold arrows represent main ones of interest. 
Double-headed arrows represent correlations. W8=worry measures at 8 weeks. 
W24=worry measures at 24 weeks. D8=delusion measures at 8 weeks. 
D24=delusion measures at 24 weeks. e1 and e2=random residuals (worry). 
e3 and e4=random residuals (delusions).
Treatment 
Total eﬀect=–0·80–5·66 × 0·27=–2·33
Mediated eﬀect=–5·66 × 0·27=–1·53 (66%) 
W8 e1 
W24 
D8 
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active techniques early, and keeps therapy precisely 
focused. Nevertheless, we do not envisage that the worry 
intervention is suﬃ  cient psychological help for these 
patients; they still had signiﬁ cant levels of worry and 
paranoia at 24 weeks follow-up—therefore the beneﬁ ts 
need to be enhanced and maintained over longer periods. 
We are now beginning to test the worry intervention in 
combination with modular interventions targeting other 
key causal factors, such as sleep disturbance, reasoning 
biases, and low self-esteem.1 The intervention will 
probably have wider applicability—eg, to patients at high 
risk of psychosis,41 patients at ﬁ rst episode of psychosis, 
and to patients with other disorders for which worry is a 
putative contributory cause.
Our investigation had three main limitations. We did 
not include a condition to control for therapist contact; 
however, this was because the most important aspect in 
this explanatory study was to show a change in the 
putative causal factor—worry—so that any eﬀ ects on 
delusions could be assessed. In this mechanistic trial, 
change in the worry thinking style needed to be 
established, not the components of therapy that might 
achieve this. For example, although we think it highly 
unlikely that befriending or supportive counselling 
would have such persistent eﬀ ects on worry and 
delusions, this possibility will have to be tested 
speciﬁ cally in this patient group. Importantly, sub-
stantial limitations exist in what can be established 
deﬁ nitively with regard to mediation. In our investi-
gation, we could not rule out the possibility that the 
intervention has merely created non-speciﬁ c change in 
a range of outcomes; against this possibility, the largest 
eﬀ ect sizes for psychiatric symptoms were for the two 
that were targeted—worry and persecutory delusions. 
These positive eﬀ ects of six sessions of therapy persisted 
at 6 months. Worry is a transdiagnostic process, and 
therefore many beneﬁ ts could probably be gained by 
reducing worry. (The control group showed some 
improvement, which is typical with the monitoring that 
occurs during a clinical trial.) We did not aim to 
measure temporal associations between changes in 
worry and changes in the delusion. Although the worry 
style was the target of intervention, and not the content 
of the delusions, the statistical models cannot 
deﬁ nitively rule out reverse causation—indeed, a 
reciprocal association between worry and paranoia is 
plausible—or possible hidden confounding (particularly 
those arising from experiences and life-events that 
occurred during the trial but were assumed to be 
unrelated to the trial intervention). Overall, we note the 
advice of Bullock and colleagues42 “to think of mediation 
analysis as a cumulative enterprise”. The study cannot 
deﬁ nitively show mediation, but the results are 
consistent with reports in the theoretical and empirical 
scientiﬁ c literature and the focus of the intervention 
techniques. Finally, follow-up was only roughly 
4–6 months after the end of treatment, though we 
regard this time as appropriate for such a short 
intervention. In clinical practice, booster sessions 
should be added. We hope to see further clinical trials 
that focus speciﬁ cally on persecutory delusions.
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CBT intervention group Control group
n Mean (SD) n Mean (SD)
6 months before the trial
Number of days in hospital 73 7·4 (26·8) 77 2.·8 (9·5)
Meetings with psychiatrist 72 2·4 (3·9) 77 2·8 (4·2)
Meetings with community psychiatric nurse 72 12·3 (9·9) 76 10·5 (10·1)
Meetings with counsellor or therapist 72 1·5 (6·2) 77 1·1 (4·7)
Visits to day-care centre 72 0·8 (4·3) 77 1·7 (10·6)
GP meetings 73 3·8 (4·8) 77 2·6 (3·2)
6 months during the trial
Number of days in hospital 73 3·5 (15·0) 77 0·2 (1·6)
Meetings with psychiatrist 65 1·6 (1·9) 71 1·8 (2·2)
Meetings with community psychiatric nurse 65 11·2 (11·3) 71 9·2 (13·9)
Meetings with counsellor or therapist (outside 
of the trial)
61 1·0 (3·6) 66 1·1 (3·4)
Visits to day-care centre 65 0·4 (2·6) 71 1·0 (6·3)
GP meetings 65 2·6 (2·6) 71 2·6 (2·5)
Data are n, mean (SD). CBT=cognitive behavioural therapy. GP=general practitioner.
 Table 3: Standard care provided in the CBT intervention group and the control group
Panel 2: Research in context
Systematic review 
We searched the ISRCTN trial registry and the PubMed database with the search terms 
“worry”, “delusions”, “persecutory”, “paranoia”, and “schizophrenia” without date restrictions, 
for English-language publications of randomised controlled trials investigating the treatment 
of worry in patients with persecutory delusions. Other than our pilot investigation12 there 
were no other such clinical trials in the medical literature. We also examined published 
meta-analyses on standard cognitive behavioural therapy (CBT) for persistent delusions or 
hallucinations, or both.43
Interpretation
After our pilot study,12 we have shown for the ﬁ rst time that treating worry leads to 
reductions in persecutory delusions. This is new for the evidence-base and consistent 
with (though not deﬁ nitive for) a role for worry as a contributory cause of paranoia. 
The eﬀ ect size is similar to standard CBT for persistent psychotic occurrences, 
according to meta-analyses.43 Standard CBT for psychosis does not include standard 
worry-intervention techniques, but our intervention is much briefer. The trial shows the 
promise of taking a focused theoretically driven approach to the treatment of psychosis.
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